Sarepta Stock Decline

News

Sarepta stock extends decline

Sarepta Therapeutics stock sinks after FDA tells company to stop shipping its bestselling drug

Sarepta stock tanked Friday after a new patient death was uncovered, spurring an FDA request to halt shipments of an unrelated drug.

MarketWatch on MSN · 1d

Sarepta stock extends decline as company declines FDA call to withdraw drug

Sarepta Therapeutics traded lower on Monday, extending a slide as the company took the unusual step of refusing a Food and Drug Administration request to stop selling a drug tied to three deaths.

U.S. News & World Report · 4h

Sarepta Shares Slide Again as Drugmaker Bows to FDA Pressure to Pause Gene Therapy

Sarepta Therapeutics is pausing shipments of its gene therapy for muscular dystrophy following several patient deaths that have attracted attention from regulators

3hon MSN

Sarepta Faces Fresh Setback. Why Now’s Not the Time to Buy the Stock.

The company agreed to voluntarily halt shipments of its experimental medicine Elevidys for Duchenne muscular dystrophy.

Hoodline2d

Sarepta Therapeutics Announces Layoff of 493 Employees, Including 80 in Ohio, Amid FDA Scrutiny and Stock Decline

Sarepta Therapeutics lays off 493 workers amid FDA probe, stock drop, and concerns over its gene therapy treatment, Elevidys.

GEN - Genetic Engineering and Biotechnology News2d

StockWatch: Sarepta Shares Nosedive after LGMD Gene Therapy Patient Dies

The death of a third patient tied to a Sarepta Therapeutics gene therapy this year sent the company’s shares nosediving 36% ...

Opendoor Technologies shares bounce again after turbulent trading

Opendoor Technologies shares are up nearly 12% as traders continue to buy the meme stock after [Monday's extreme volatility]( ...

Sarepta Therapeutics crisis is huge blow to Duchenne families, company

Sarepta rebuffed a call from the Food and Drug Administration to halt all shipments of its gene therapy for Duchenne muscular ...

Forbes4y

Sarepta, Vertex, Neurocrine: There’s Deep Value In These ... - Forbes

Sarepta Therapeutics, a company that develops RNA-targeted therapeutics and gene therapy for the treatment of rare diseases, has seen its stock decline by 54% year-to-date. The decline is due ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results